Results 141 to 150 of about 1,323,755 (303)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

The Effect of Prolonged Exposure to Extremely Low Frequency Electromagnetic Fields on the β2 Adrenergic System Activity in the Small Intestine of Male Rats

Journal of Fasa University of Medical Sciences, 2016
Background & Objective: Electromagnetic waves with the frequencies of 0–300 Hz and the intensity of 0.1–100 millitesla can affect several cellular activities.
Esmaeil Khoshnam, Marzyeh Jaafari, Amin Bahaoddini, Maryam Owjfard   +3 more
doaj  

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B). [PDF]

J Neurol
Miesenberger AS, Arlt FA, Koschützke L, Gebert P, Heidecke H, Schulze-Forster K, Catar RA, Moll G, Harms C, Kufner A, Liman T, Prüss H, Endres M, Sperber PS.   +13 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Antitumour Effects of β-Blockers: A Narrative Review of the Literature. [PDF]

Curr Issues Mol Biol
Melissaridou D, Savvidou OD, Lianou I, Kaspiris A, Korkolopoulou P, Papadimitriou E, Papagelopoulos PJ.   +6 more
europepmc   +1 more source

The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment

British Journal of Pharmacology, EarlyView.
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton, Fraser Nunn, Erika Lace, Álvaro Lorente‐Macías, Rachel Toth, Asier Unciti‐Broceta, Tim G. Hales   +6 more
wiley   +1 more source

ATP Release and Purinergic Signaling Potentiate β-Adrenergic Effects on Brown Adipocytes. [PDF]

Acta Physiol (Oxf)
Tozzi M, Berggreen EB, Zhang R, Gudiksen A, Li W, Matz MB, Pilegaard H, Hansen JB, Novak I.   +8 more
europepmc   +1 more source

Beta Adrenergic Receptor [PDF]

, 2020
openaire   +1 more source